Nearly £10bn has been wiped off the stock market value of AstraZeneca over concerns that a new lung cancer drug may not be as successful as had been hoped.

1238317363

Reuters

United Kingdom

AstraZeneca shares drop as lung cancer trial update lags expectations

AstraZeneca said on Monday an experimental precision drug slowed progression of lung cancer in a late-stage trial, but the company's shares fell as much as 6% as analysts said the benefits may not be as pronounced as hoped.

Ad Fontes Media

All Sides

Media Bias/Fact Check

The Woodbridge Company

AstraZeneca Plc shares fell as results from a high-level study of a new cancer medicine raised concern the drug might not work as well as anticipated.

Bloomberg

Michael Bloomberg

The Vanguard Group

Howard Buffett

BlackRock

United States

New AstraZeneca Cancer Drug Shows Potential in Key Study

By Maggie Fick and Ludwig Burger (Reuters) - AstraZeneca said on Monday an experimental precision drug slowed progression of lung cancer in a late-stage trial, but the company's shares fell as much as 6% as

Herring Networks

San Diego

San Diego County

California

AstraZeneca Plc shares fell as results from a high-level study of a new cancer medicine raised concern the drug might not work as well as anticipated.The

Al Arabiya

Middle East News FZ LLC

Saudi Arabia

AstraZeneca shares drop on concern over lung cancer trial results

Trial studied patients with advanced non-small cell lung cancer

Financial Times

Nikkei Inc.

London

Greater London

England

AstraZeneca shares fall after cancer drug trial disappoints investors

The company also reported some deaths in the trial, raising safety concerns. The trial is continuing because the data isn’t fully mature yet.

Australian Financial Review

Nine Entertainment Co.

Sydney

New South Wales

Australia

AstraZeneca drops on concern over lung cancer trial

Market value drops by 6% on concerns that new lung cancer drug may not be as successful as hopedNearly £10bn has been wiped off the stock market value of AstraZeneca over concerns that a new lung cancer drug may not be as successful as had been hoped.Shares in the Anglo-Swedish pharmaceutical company fell by as much as 6% on Monday morning after it published the first results from its phase 3 trial for datopotamab deruxtecan, making it the bigge…

The Guardian

AstraZeneca stock value falls by nearly £10bn after cancer drug trial results

Europe

Cancer

Business

European Economy

AstraZeneca

US Economy

Stock Markets

Health

UK Economy

Medical

Cambridge, England

Cambridge

Cambridgeshire

AstraZeneca said an experimental precision drug slowed progression of lung cancer in a late-stage trial. The company's shares fell as much as 6% as analysts said the benefits may not be as pronounced as hoped. The drug, datopotamab deruxtecan, is being jointly developed with Japan's Daiichi Sankyo (4568.T)

AstraZeneca stock value falls by nearly £10bn after cancer drug trial results

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics